According to GlobalData’s company profile on ChemoCentryx, was a key innovation area identified from patents.

Treatment of pancreatic cancer using pharmaceutical combinations

A recently granted patent (Publication Number: US11890276B2) discloses a method for controlling adenocarcinoma in patients by administering a pharmaceutical combination containing a compound of Formula I. The compound's specific structure is defined by various parameters, including the presence of halogen or methyl groups in R1, halogen or C1-6 haloalkyl in R2, and hydrogen in R4, among others. The method aims to provide benefits such as tumor size reduction, suppression of tumor growth, increased survival rates, and various other positive outcomes related to pancreatic adenocarcinoma.

Furthermore, the patent outlines the use of additional therapeutic compounds in combination with the Formula I compound, including a wide range of established pharmaceuticals like gemcitabine, paclitaxel, and FOLFIRINOX. The administration of the compound can be oral, once or twice a day, with specific dosage ranges between 50 mg to 300 mg, with a preferred effective amount of 150 mg. The patent's comprehensive list of additional therapeutic compounds covers a vast array of established cancer treatments, showcasing the potential for combination therapies to enhance the efficacy of adenocarcinoma treatment. This patent provides a detailed framework for a method that could significantly impact the management and outcomes of patients suffering from various forms of adenocarcinoma.

To know more about GlobalData’s detailed insights on ChemoCentryx, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed